Astral's first multi-state fusion reactor

A New Class of Fusion Reactor

Astral Systems has invented and demonstrated the first of its kind multi-state fusion device, enabling orders of magnitude improved fusion rates on a reactor architecture that embodies a quarter century of engineering design. Our reactors are compact in size with high particle flux and unparalleled lifetime performance. We are applying our breakthrough technology to create meaningful solutions to prescient problems today.

Next-generation compact fusion reactors for immediate medical and industrial applications

By applying recently discovered breakthroughs in physics, we have increased the performance of our TRL 9 reactors by over an order of magnitude.  Our systems unlock a wide variety of medical, industrial, and research applications well before any fusion plant is plugged into the grid. We are developing innovative system designs to address global challenges such as those in health access and zero carbon energy.

Dr Tom-Wallace Smith and Talmon Firestone at the JET fusion reactor in Oxford.

Enabling Fusion Power

Through partnerships with organisations such as the UKAEA, Astral has already provided valuable data using its reactor technologies that will accelerate the development of fusion power. Our reliable and high-performance compact fusion reactors are an ideal testbed for understanding what a full-scale fusion power plant will look like and how it might behave during operation; providing a tunable and versatile platform for experimentation and high-quality data generation.

Due to the ultra-compact and modular nature of our systems, we are able to design fusion research facilities built around a plurality or cluster of Astral reactors to maximize neutron flux within a focused test volume.

Global Health Access

Nuclear medicine is a vital tool used around the world to diagnose and treat life-threatening diseases every day. Due to unreliable supply chains that rely on ageing fission reactors in Europe and abroad, many clinicians in the UK and elsewhere are unable to access the radioisotopes needed to deliver this critical care.

We aim to provide medical isotope production at the point of care for both diagnostic and therapeutic applications. Our cheaper, cleaner, and safer fusion-based alternative technology can be be situated near to or within hospital hubs. This will dramatically increase the diagnostic and treatment techniques available to clinicians; reducing hospital wait times and costs whilst improving quality of care.

Supporters and Collaborators

Photos and website design contributions by